Impact of baseline luteinizing hormone (LH) level and anti-Müllerian hormone (AMH) on pregnancy outcomes in polycystic ovary syndrome (PCOS) patients undergoing IVF/ICSI cycle in antagonist protocol
Global Reproductive Health · 2023-10 · 8 (3)
DOI: 10.1097/grh.0000000000000071 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Global Reproductive Health, 2023-10. Verfasst von Amina Oumeziane und 12 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Polycystic ovary syndrome (PCOS) is a complex endocrine and metabolic disorder often associated with infertility. There are several factors that could impair the pregnancy outcomes of PCOS patients. The latter endocrine profile along with high baseline luteinizing hormone (LH), high LH/follicle-stimulating hormone ratio, as well as high anti-Müllerian hormone (AMH) levels appear detrimental for patients undergoing In vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI). The objective of this study is to evaluate the impact of baseline LH and AMH levels on pregnancy outcomes in PCOS patients performing IVF/ICSI cycles in an antagonist protocol. Materials and methods: The current investigation is a retrospective cohort study conducted at IVF Tiziri Center in Algiers on PCOS patients undergoing IVF/ICSI from January 2017 to March 2021. According to the Rotterdam criteria, patients aged between 23 and 42 years were divided into 2 groups: group 1 (G1) =91 patients; group 2 (G2) =100 all patients had an LH level >10 IU/L. Both groups had AMH levels >5 ng/mL. Controlled ovarian stimulation was done with a fixed antagonist protocol, as for the ovulation it was triggered with human chorionic gonadotropin or gonadotropin-releasing hormone agonist. Fresh and frozen embryo transfers were, thereafter, evaluated. Concerning the statistical analysis, it was done with SPSS software.
Results
The mean LH level was 15.16±7.08 for G1 versus 5.7±1.86 for G2 ( P =10 −6 ), mean LH/follicle-stimulating hormone ratio 2.71±1.36 in G1 versus 1.05±0.44 ( P =10 −6 ) and mean AMH level was 9.27±3.90 for G1 versus 7.53±2.76 for G2 with ( P 0.05); the ongoing pregnancy rate (OPR) was 28.6% in G1 versus 47% in G2 ( P =0.078); and the miscarriage rate was 32.4% for G1 versus 12.9 for G2 ( P =0.072). A univariate analysis was performed with all confounder factors supposed to impact pregnancy outcomes: AMH level did not impact pregnancy outcomes, whereas LH level
Zitieren
APA
Oumeziane, A., Aggad, A., Melbani, Y., Nanouche, F., Barbara, S., Djerroudib, K., Bourihane, R., Tazairt, N., Mouhoub, S., Lacheheb, A., Chemoul, S., Chabane, N., & Boucekkine, N. (2023). Impact of baseline luteinizing hormone (LH) level and anti-Müllerian hormone (AMH) on pregnancy outcomes in polycystic ovary syndrome (PCOS) patients undergoing IVF/ICSI cycle in antagonist protocol. Global Reproductive Health, 8(3). https://doi.org/10.1097/grh.0000000000000071
Vancouver
Oumeziane A, Aggad A, Melbani Y, Nanouche F, Barbara S, Djerroudib K, et al. Impact of baseline luteinizing hormone (LH) level and anti-Müllerian hormone (AMH) on pregnancy outcomes in polycystic ovary syndrome (PCOS) patients undergoing IVF/ICSI cycle in antagonist protocol. Global Reproductive Health. 2023;8(3). doi:10.1097/grh.0000000000000071
BibTeX
@article{Oumeziane2023,
author = {Oumeziane, Amina and Aggad, Amira and Melbani, Yasmina and Nanouche, Fatima and Barbara, Samira and Djerroudib, Karima and Bourihane, Rachida and Tazairt, Nedjma and Mouhoub, Samia and Lacheheb, Ahlem and Chemoul, Samia and Chabane, Nawel and Boucekkine, Nadjia},
title = {Impact of baseline luteinizing hormone (LH) level and anti-Müllerian hormone (AMH) on pregnancy outcomes in polycystic ovary syndrome (PCOS) patients undergoing IVF/ICSI cycle in antagonist protocol},
journal = {Global Reproductive Health},
year = {2023},
volume = {8},
number = {3},
doi = {10.1097/grh.0000000000000071}
}
EUVIMED